Compare Cassava Sciences Inc (FLNA) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Verisign, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Verisign, Inc. trades at $275.27 (market cap $24.62B). The key difference: Verisign, Inc. is far larger — about 463.3× Cassava Sciences Inc's market cap, and Verisign, Inc. pays a 1.2% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | VRSN | |
|---|---|---|
Market Cap | $53.14M | $24.62B |
Sector | Health | Technology |
52-Week High | $4.64 | $310.00 |
52-Week Low | $1.09 | $211.49 |
Enterprise Value | -$33.43M | $25.86B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VeriSign (VRSN) trades at $268.85, down 0.54% today, with a bullish technical outlook and strong fundamentals. The stock shows consistent revenue growth, reaching $1.66B in 2025, and maintains high profit margins near 50%. Recent Q1 2026 earnings beat expectations at $2.34 EPS, though Q4 2025 missed. Analyst consensus is bullish with a $325.25 price target, and technical indicators suggest support at $265 with resistance at $271.
VRSN offers stable growth driven by its monopoly on .com and .net domains, but faces risks from AI disruption and contract renewals. The stock is fairly valued with a P/E of 29.89, and institutional sentiment is positive. Key risks include high debt levels and competitive threats, yet the company's cash flow and dividend payments support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
